Otsuka Pharmaceuticals is the top private funder of tuberculosis (TB) research and drug development in the world. Last year, Otsuka established a Geneva-based subsidiary – Otsuka SA – to serve as “the company’s central operations for developing and implementing public health policies and corporate social responsibility programs in connection with its global TB program,” according to the company’s website.
As part of our reporting in advance of World TB Day on Saturday (March 24), Science Speaks interviewed Patrizia Carlevaro, PhD, the leader of Otsuka SA, to discuss Otsuka’s latest research to address drug-resistant forms of TB, the world’s emerging tuberculosis “hotspots,” and other efforts by the subsidiary organization to tackle TB.
In advance of World TB Day (Saturday, March 24) Science Speaks sat down with tuberculosis (TB) expert Lee B. Reichman, MD, MPH, founding executive director of the New Jersey Medical School Global Tuberculosis Institute, to discuss the spread of drug-resistant TB and what he thinks are the most promising advances coming down the scientific pipeline. […]
In this third post in a series of conversations with officials at the U.S. Centers for Disease Control and Prevention (CDC) discussing the CDC’s role in global HIV and tuberculosis research and development, Science Speaks sat down with John Vertefeuille, PhD – the country director for CDC in Haiti. There he leads a team of 55 and […]
This is the second in a series of conversations with officials at the Centers for Disease Control and Prevention (CDC), discussing the CDC’s role in global health and connections with HIV and TB activities. The following interview is with Scott Dowell, MD, MPH. Dr. Dowell is the Director of the Division of Global Disease Detection […]
This is the first in a series of conversations with officials at the Centers for Disease Control and Prevention (CDC), discussing the CDC’s role in global HIV and tuberculosis research and development. The following interview is with Kayla Laserson, Director of the Kenya Medical Research Institute (KEMRI)/CDC Field Research Station in Kisumu, Kenya. Dr. Laserson […]
Young investigators and Fogarty students presented select posters on global health at a special gallery during the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Boston last month. The event was sponsored by the National Insitutes of Health Office of AIDS Research, the Accordia Global Health Foundation and the IDSA Education and Research Foundation. In this video interview, Sten Vermund, MD, PhD, director of the Institute for Global Health at Vanderbilt University, discusses one of the student “highlights” of the evening – Krutika Kuppalli, MD, from the University of California, San Diego – and her research on HIV and leptospirosis in Chenai, India.
Last week the World Health Organization (WHO) and the TB Alliance joined with pharmaceutical companies AstraZeneca, Bayer, Sanofi and Tibotec in an innovative agreement to share information about tuberculosis (TB) compounds in their drug pipelines and speed the development of new regimens, including the most promising multi-drug treatments, regardless of sponsor. Science Speaks sat down with Mel Spigelman, MD, president and chief executive officer of the TB Alliance, to discuss the new collaboration, which promising drug combinations are coming down the pipeline, and how their work is expediting the process.
Science Speaks sits down with Dr. Chris Ford, founding member of the organization International Doctors for Healthy Drug Policies (IDHDP), to discuss the goals of the IDHDP, what drug policies are most harmful, and where the need for drug policy reform is most urgent.
The following is an interview with Jonathan Smith, writer and director of a documentary-in-progress entitled “They Go to Die,” highlighting the brutal toll of the dual HIV/TB epidemics among South Africa’s mine workers. Science Speaks sat down with Smith to discuss the film, what the epidemics look like on the ground in southern Africa, and what he is doing to raise the money needed to complete his documentary.
The following is an interview with Charles B. Holmes, MD, MPH, chief medical officer and Director of Research & Science at the Office of the U.S. Global AIDS Coordinator (OGAC). This is the last interview in a Science Speaks “motivator” series with staff members at OGAC, which oversees the U.S. President’s Emergency Plan for AIDS […]